Non-invasive prenatal testing: A review of international implementation and challenges

International Journal of Women's Health

Volumn 7, Issue , 2015, Pages 113-126

  Allyse, Megan ^a   Minear, Mollie A ^b   Berson, Elisa ^c   Sridhar, Shilpa ^c   Rote, Margaret ^c   Hung, Anthony ^c   Chandrasekharan, Subhashini ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY   (United States)

^c Duke University   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromosome aneuploidies; Ethics; Genetic testing; Global; Implementation; Noninvasive prenatal testing (NIPT)

Indexed keywords

ABORTION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC KIT; DOWN SYNDROME; GENETIC COUNSELING; HEALTH CARE COST; HUMAN; INCOME; KLINEFELTER SYNDROME; LAW SUIT; LEGAL ASPECT; MEDICAL ETHICS; NON INVASIVE MEASUREMENT; NON INVASIVE PRENATAL GENETIC TESTING; PATENT; PRACTICE GUIDELINE; PREGNANCY TERMINATION; PRENATAL DIAGNOSIS; PRENATAL SCREENING; REVIEW; SENSITIVITY AND SPECIFICITY; SEX CHROMOSOME ABERRATION; TRISOMY 13; TRISOMY 16; TRISOMY 18; TRISOMY 21; TURNER SYNDROME;

EID: 84921815149     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S67124     Document Type: Review

References (167)

1. Shamshirsaz AA, Benn P, Egan JF. The role of second-trimester serum screening in the post-first-trimester screening era. Clin Lab Med. 2010;30(3):667–676.
2. Russo ML, Blakemore KJ. A historical and practical review of frst trimester aneuploidy screening. Semin Fetal Neonatal Med. 2014;19(3): 183–187.
3. Norwitz ER, Levy B. Noninvasive prenatal testing: the future is now. Rev Obstet Gynecol. 2013;6(2):48–62.
4. Lo YM, Corbetta N, Chamberlain P F, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485–487.
5. Wright CF, Burton H. The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis. Hum Reprod Update. 2009;15(1):139–151.
6. Chiu RW, Lo YM. Non-invasive prenatal diagnosis by fetal nucleic acid analysis in maternal plasma: the coming of age. Semin Fetal Neonatal Med. 2011;16(2):88–93.
7. The American College of Obstetricians and Gynecologists Committee on Genetics [homepage on the Internet]. The Society for Maternal-Fetal Medicine Publications Committee. Committee Opinion Number 545; 2012. Noninvasive Prenatal Testing for Fetal Aneuploidy. Available from:http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Genetics/Noninvasive-Prenatal-Testing-for-Fetal-Aneuploidy. Accessed July 28, 2014.
8. Sayres LC, Cho MK. Cell-Free fetal nucleic acid testing: A review of the technology and its applications. Obstet Gynecol Sur. 2011;66(7):431–442.
9. Hall A, Bostanci A, Wright CF. Non-invasive prenatal diagnosis using cell-free fetal DNA technology: Applications and implications. Public Health Genomics. 2010;13(4):246–255.
10. Hung EC, Chiu RW, Lo YM. Detection of circulating fetal nucleic acids: A review of methods and applications. J Clin Pathol. 2009;62(4): 308–313.
11. Boon EM, Faas BH. Benefits and limitations of whole genome versus targeted approaches for noninvasive prenatal testing for fetal aneuploidies. Prenat Diagn. 2013;33(6):563–568.
12. Liao GJ, Gronowski AM, Zhao Z. Non-invasive prenatal testing using cell-free fetal DNA in maternal circulation. Clin Chim Acta. 2014;428: 44–50.
13. Papageorgiou EA, Koumbaris G, Kypri E, Hadjidaniel M, Patsalis PC. The epigenome view: An effort towards non-invasive prenatal diagnosis. Genes. 2014;5(2):310–329.
14. Chiu RW, Lo YM. Noninvasive prenatal diagnosis empowered by high-throughput sequencing. Prenat Diagn. 2012;32(4):401–406.
15. Nicolaides, Syngelaki A, Ashoor G, Birdir, Touzet G. Noninvasive prenatal testing for fetal trisomies in a routinely screened frst-trimester population. Am J Obstet Gynecol. 2012;207(5):374. e1–e6.
16. Ashoor G, Syngelaki A, Wang E, et al. Trisomy 13 detection in the frst trimester of pregnancy using a chromosome-selective cell-free DNA analysis method. Ultrasound Obstet Gynecol. 2013;41(1):21–25.
17. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn. 2012;32(13): 1233–1241.
18. Bianchi D, Platt L, Golberg J, Abuhamad A, Sehnert A, Rava R. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(5):890–901.
19. Bianchi DW, Platt LD, Golberg JD, Abuhamad AZ, Sehnert AJ, Rava R P, MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-Wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(5): 890–901.
20. Norton ME, Brar H, Weiss J, et al. Non-Invasive chromosomal evaluation (NICE) study: Results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;207(2):137. e1–e8.
21. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med. 2011;13(11):913–920.
22. Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifes trisomy 18 and trisomy 13 as well as Down syndrome: An international collaborative study. Genet Med. 2012;14(3): 296–305.
23. Ilumina [homepage on the Internet]. Clinical data; Analytical validation of the verif prenatal test: enhanced test performance for detecting trisomies 21, 18, and 13 and the option for classifcation of sex chromosome status. Available from:http://www.veriftest.com/clinical-data/. Accessed June 15, 2014.
24. Panorama Prenatal Screen [homepage on the Internet]. The next generation of non-invasive prenatal screening. Available from: http://www.panoramatest.com/clinical_data. Accessed June 15, 2014.
25. Sequenom Laboratories [homepage on the Internet]. The Science of Revolutionizing Prenatal Care. Available from: http://sequenom.uber-fip.com/i/212031. Accessed June 15, 2014.
26. Wald NJ, Bestwick J P. Incorporating DNA sequencing into current prenatal screening practice for down’s syndrome. PLoS One. 2013;8(3):e58732.
27. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfdna analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med. 2013;26(12): 1180–1185.
28. Shaw S W, Chen C P, Cheng PJ. From down syndrome screening to noninvasive prenatal testing: 20 years’ experience in taiwan. Taiwan J Obstet Gynecol. 2013;52(4):470–474.
29. Choi H, Lau TK, Jiang FM, et al. Fetal aneuploidy screening by maternal plasma DNA sequencing: ‘False positive’ due to confned placental mosaicism. Prenat Diagn. 2013;33(2):198–200.
30. Morain, Greene M F, Mello MM. A new era in noninvasive prenatal testing. N Engl J Med. 2013;369(6):499–501.
31. Pollack BA. A less risky Down syndrome test is developed. The New York Times. October 17, 2011. Available from:http://www.nytimes.com/2011/10/18/business/sequenom-test-for-down-syndrome-raises-hopes-and-questions.html?pagewanted=all&_r=1&. Accessed August 25, 2014.
32. Dickens BM. Ethical and legal aspects of noninvasive prenatal genetic diagnosis. Int J Gynaecol Obstet. 2014;124(2):181–184.
33. Tabor A, Vestergaard CH, Lidegaard Ø. Fetal loss rate after chorionic villus sampling and amniocentesis: An 11-year national registry study. Ultrasound Obstet Gynecol. 2009;34(1):19–24.
34. Allyse M, Sayres LC, Goodspeed TA, Cho MK. Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age. J Perinatol. 2014;34(6):429–434.
35. Markens S, Browner CH, Press N. ‘Because of the risks’: How US pregnant women account for refusing prenatal screening. Soc Sci Med. 1999;49(3):359–369.
36. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: A systematic review and meta-analysis. JAMA. 2011;306(6):627–636.
37. Goodspeed TA, Allyse M, Sayres LC, Norton ME, Cho MK. Translating cell-free fetal DNA technology: Structural lessons from non-invasive RhD blood typing. Trends Biotechnol. 2013;31(1):7–9.
38. Clausen FB. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care. Prenat Diagn. 2014;34(5): 409–415.
39. Vora NL, O’Brien BM. Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies. Obstet Gynecol. 2014;123(5): 1097–1099.
40. Sequenom, Inc. Sequenom laboratories launches the enhanced sequencing series for the Maternit21™ Plus test [press release]. San Diego, CA: Sequenom Laboratories; [October 22, 2013]. Available from: http://www.sequenom.com/press/sequenom-laboratories-launches-enhanced-sequencing-series-maternit21-plus-test. Accessed July 28, 2014.
41. Sequenom [webpage on the Internet]. Sequenom Laboratories Presents New Data on the Enhanced Sequencing Series for the MaterniT21™ Plus Laboratory-Developed Test At 18th International Conference on Prenatal Diagnosis and Therapy. San Diego, USA, July 22, 2014. Available from:http://www.sequenom.com/press/sequenom-laboratories-presents-new-data-enhanced-sequencing-series-maternit21-plus-laboratory. Accessed August 29, 2014.
42. Lench N, Barrett A, Fielding S, et al. The clinical implementation of non-invasive prenatal diagnosis for single-gene disorders: challenges and progress made. Prenat Diagn. 2013;33(6):555–562.
43. Chitty LS, Bianchi DW. Noninvasive prenatal testing: the paradigm is shifting rapidly. Prenat Diagn. 2013;33(6):511–513.
44. Yo u Y, Sun Y, Li X, et al. Integration of targeted sequencing and NIPT into clinical practice in a Chinese family with maple syrup urine disease. Genet Med. 2014;16(8):594–600.
45. Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profle of the fetus. Sci Transl Med. 2010;2(61):61ra91.
46. Kitzman JO, Snyder M W, Ventura M, et al. Noninvasive whole-genome sequencing of a human fetus. Sci Transl Med. 2012;4(137):137ra76.
47. Lau TK, Chan MK, Lo PS, et al. Clinical utility of noninvasive fetal trisomy (NIFTY) test – early experience. J Matern Fetal Neonatal Med. 2012;25(10):1856–1859.
48. Agarwal A, Sayres LC, Cho MK, Cook-Deegan R, Chandrasekharan S. Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn. 2013;33(6):521–531.
49. Chandrasekharan S, Minnear MA, Hung A, Allyse M. Noninvasive prenatal testing goes global. Sci Transl Med. 2014;6(231):231fs15.
50. Transparency Market Research [homepage on the Internet]. Non- Invasive prenatal testing (NIPT) market (maternit21 PLUS, verif, harmony, panorama, NIFTY, prenatest and bambnitest) – global industry analysis, size, share, growth, trends and forecast, 2013–2019. Available from: http://www.transparencymarketresearch.com/noninvasive-prenatal-diagnostics-market.html2014. Accessed June 15, 2014.
51. Ariosa Diagnostics [webpage on the Internet]. Harmony prenatal test clinical data. Available from: http://www.ariosadx.com/reviewclinical-data/clinical-data/. Accessed June 15, 2014.
52. Integrated Genetics [webpage on Internet]. informaSeq Prenatal Test. Available from:https://www.labcorp.com/wps/wcm/connect/IntGeneticsLib/integratedgenetics/home/our+services/reproductive+testing/informaseq+prenatal+test. Accessed September 2, 2014.
53. Morris S, Karlsen S, Chung N, Hill M, Chitty LS. Model-Based analysis of costs and outcomes of non-invasive prenatal testing for down’s syndrome using cell free fetal DNA in the UK national health service. PLoS One. 2014;9(4):e93559.
54. Heger M. As maternit21 drives spike in diagnostic revenue, sequenom predicts 2 5K tests sold in 2 012. Genomeweb. March 14, 2012. Available from: http://www.genomeweb.com/sequencing/maternit21-drives-spike-diagnostic-revenue-sequenom-predicts-25k-tests-sold-2012. Accessed August 29, 2014.
55. Heger M. As rivals vie for share of noninvasive trisomy testing market, physicians see value for screening. GenomeWeb. July 3, 2012. Available from: http://www.genomeweb.com/sequencing/rivals-vie-share-noninvasive-trisomy-testing-market-physicians-see-value-screeni. Accessed August 29, 2014.
56. Heger M. Sequencing-Based fetal testing market heats up as verinata plans 2012 launch for down syndrome dx. GenomeWeb. May 2, 2011. Available from: http://www.genomeweb.com/sequencing/sequencing-based-fetal-testing-market-heats-verinata-plans-2012-launch-down-synd. Accessed August 29, 2014.
57. Platt LD, Janicki MB, Prosen T, et al. Impact of noninvasive prenatal testing in regionally dispersed medical centers in the United States. Am J Obstet Gynecol. Epub April 3, 2014.
58. Haymon L, Simi E, Moyer K, Aufox S, Ouyang DW. Clinical implementation of noninvasive prenatal testing among maternal fetal medicine specialists. Prenat Diagn. 2014;34(5):416–423.
59. Schmitz D, Netzer C, Henn W. An offer you can’t refuse? Ethical implications of non-invasive prenatal diagnosis. Nat Rev Genet. 2009;10(8):515.
60. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninva-sive prenatal screening for fetal aneuploidy. Genet Med. 2013;15(5): 395–398.
61. Benn P, Borell A, Chiu R, et al. Position statement from the aneuploidy screening committee on behalf of the board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2013;33(7):622–629.
62. [No authors listed]. Position statement from the Italian College of Fetal Maternal Medicine: Non-invasive prenatal testing (NIPT) by maternal plasma DNA sequencing. J Prenat Med. 2013;7(2):19–20.
63. Bianchi D, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. NEJM. 2014;370(9):799–808.
64. Benn P, Cuckle H. Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasma. Prenat Diagn. 2014;34(8): 778–783.
65. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH. Chromosome-selective sequencing of maternal plasma cell-free DNA for frst-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012;206(4):322. e1–e5.
66. Smith M, Lewis KM, Holmes A, Visootsak J. A case of false negative NIPT for down syndrome-lessons learned. Case Rep Genet. 2014; 2014:823504.
67. Verweij EJ, de Boer MA, Oepkes D. Non-invasive prenatal testing for trisomy 13; more harm than good? Ultrasound Obstet Gynecol. 2014;44(1):112–114.
68. Srebniak MI, Diderich KE, Noomen P, Dijkman A, Vries F, Opstal DV. Abnormal NIPT results concordant with the karyotype of the cytotro-phoblast, but not refecting the abnormal fetal karyotype. Ultrasound Obstet Gynecol. 2014;44(1):109–111.
69. Centre Hospitalier Universitaire de Québec, CHU de Québec. Study of the Effcacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood (PEGASUS). Available from: http:// clinicaltrials.gov/show/NCT01925742. NLM identifer: NCT01925742. Accessed July 28, 2014.
70. Reliable Accurate Prenatal non-Invasive Diagnosis [homepage on the Internet]. Guides to NIPD/NIPT. Available from: http://www.rapid.nhs. uk/. Accessed July 28, 2014.
71. Manegold-Brauer G, Kang Bellin A, Hahn S, et al. A new era in prenatal care: Non-invasive prenatal testing in Switzerland. Swiss Med Wkly. 2014;144:w13915.
72. Pettit KE, Hull AD, Korty L, Jones MC, Pretorius DH. Noninvasive prenatal testing: A replacement for chorionic villus sampling and amniocentesis for advanced maternal age? Obstet Gynecol. 2014;123 Suppl 1:165S–166S.
73. Rad S, Turner AL, Beauchamp S, Aghajanian P, Williams J , Esakoff TF. Noninvasive prenatal testing compared with invasive diagnostic testing in the setting of an abnormal state aneuploidy screen. Obstet Gynecol. 2014;123 Suppl 1:100S.
74. O’Leary P, Maxwell S, Murch A, Hendrie D. Prenatal screening for Down syndrome in Australia: Costs and benefts of current and novel screening strategies. Aust N Z J Obstet Gynaecol. 2013;53(5):425–433.
75. Ohno M, Caughey A. The role of noninvasive prenatal testing as a diagnostic versus a screening tool – a cost-effectiveness analysis. Prenat Diagn. 2013;33(7):630–635.
76. Devers PL, Cronister S, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: The position of the national society of genetic counselors. J Genet Couns. 2013;22(3):291–295.
77. Deans Z, Newson AJ. Should non-invasiveness change informed consent procedures for prenatal diagnosis? Health Care Anal. 2011;19(2): 122–132.
78. van Schendel RV, Kleinveld JH, Dondorp WJ, et al. Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. Eur J Hum Genet. Epub March 19, 2014.
79. Constantine M, Allyse M, Rockwood T, Wall M, De Vries R. Imperfect informed consent for prenatal screening: Lessons from the quad screen. Clinical Ethics. 2014;9(1):17–27.
80. Favre R, Duchange N, Vayssière C, et al. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study. Prenat Diagn. 2007;27(3):197–205.
81. van den Berg M, Timmermans DR, ten Kate L P, van Vugt JM, van der Wal G. Informed decision making in the context of prenatal screening. Patient Educ Couns. 2006;63(1–2):110–117.
82. van den Heuvel A, Chitty L, Dormandy E, et al. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. Patient Educ Couns. 2010;78(1):24–28.
83. Silcock C, Liao L-M, Hill M, Chitty LS. Will the introduction of non-invasive prenatal testing for down’s syndrome undermine informed choice? Health Expectations. Epub February 20, 2014.
84. Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. Curr Opin Obstet Gynecol. 2010;22(2):128–134.
85. Deans Z, Hill M, Chitty LS, Lewis C. Non-invasive prenatal testing for single gene disorders: exploring the ethics. Eur J Hum Genet. 2013;21(7):713–718.
86. de Jong A, Dondorp WJ, Frints SG, de Die-Smulders CE, de Wert GM. Advances in prenatal screening: the ethical dimension. Nat Rev Genet. 2011;12(9):657–663.
87. de Jong A, Dondorp WJ, de Die-Smulders CE, Frints SG, de Wert GM. Non-invasive prenatal testing: ethical issues explored. Eur J Hum Genet. 2010;18(3):272–277.
88. Pollack A. Confict potential seen in genetic counselors. The New York Times. July 13, 2012.
89. Bensend TA, Veach PM, Niendorf KB. What’s the harm? Genetic counselor perceptions of adverse effects of genetics service provision by non-genetics professionals. J Genet Couns. 2014;23(1): 48–63.
90. Horsting JM, Dlouhy SR, Hanson K, Quaid K, Bai S, Hines KA. Genetic counselors’ experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy. J Genet Couns. 2014;23(3): 377–400.
91. Markens S. “It just becomes much more complicated”: Genetic counselors’ views on genetics and prenatal testing. New Genetics and Society. 2013;32(3):302–321.
92. Rothman BK. The Tentative Pregnancy: How Amniocentesis Changes the Experience of Motherhood. New York: Norton; 1993.
93. Asch A, Wasserman D. Where is the sin in synecdoche? Prenatal testing and the parent-child relationship. In: Quality of Life and Human Difference: Genetic Testing, Health Care, and Disability. New York: Cambridge University Press; 2005:172–216.
94. Costa JM, Benachi A, Gautier E. New strategy for prenatal diagnosis of x-linked disorders. N Engl J Med. 2002;346(19):1502.
95. Maron DF. Virtual doctor visits gaining steam in “geneticist deserts”. Scientifc American. April 21, 2014. Available from: http://www.scientifcamerican.com/article/virtual-doctor-visits-gaining-steam/. Accessed August 25, 2014.
96. Farrimond HR, Kelly SE. Public viewpoints on new non-invasive prenatal genetic tests. Public Underst Sci. 2013;22(6):730–744.
97. Wertz DC, Knoppers BM. Serious genetic disorders: Can or should they be defned? Am J Med Genet. 2002;108(1):29–35.
98. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental fndings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–574.
99. de Jong A, Dondorp WJ, Macville M V, de Die-Smulders CE, van Lith JM, de Wert GM. Microarrays as a diagnostic tool in prenatal screening strategies: Ethical reflection. Hum Genet. 2014;133(2):163–172.
100. Bernhardt BA, Kellom K, Barbarese A, Faucett WA, Wapner RJ. An exploration of genetic counselors’ needs and experiences with prenatal chromosomal microarray testing. J Genet Couns. Epub February 27, 2014.
101. Bernhardt BA, Soucier D, Hanson K, Savage MS, Jackson L, Wapner RJ. Women’s experiences receiving abnormal prenatal chromosomal microarray testing results. Genet Med. 2013;15(2):139–145.
102. Tabor HK, Murray JC, Gammill HS, et al. Non-invasive fetal genome sequencing: Opportunities and challenges. Am J Med Genet A. 2012;158A(10):2382–2384.
103. Kellogg G, Slattery L, Hudgins L, Ormond K. Attitudes of mothers of children with down syndrome towards noninvasive prenatal testing. J Genet Couns. Epub February 1, 2014.
104. Parens E, Asch A. Special supplement: The disability rights critique of prenatal genetic testing refections and recommendations. Hastings Cent Rep. 1999;29(5):S1–S22.
105. Parens E, Asch A. Disability rights critique of prenatal genetic testing: Refections and recommendations. Ment Retard Dev Disabil Res Rev. 2003;9(1):40–47.
106. Roberts CD, Stough LD, Parrish LH. The role of genetic counseling in the elective termination of pregnancies involving fetuses with disabilities. J Spec Educ. 2002;36(1):48–55.
107. Skotko BG, Levine S P. What the other children are thinking: Brothers and sisters of persons with down syndrome. Am J Med Genet C Semin Med Genet. 2006;142C(3):180–186.
108. Skotko BG, Levine S P, Goldstein R. Self-perceptions from people with Down syndrome. Am J Med Genet A. 2011;155A(10):2360–2369.
109. Skotko. With new prenatal testing, will babies with Down syndrome disappear? Arch Dis Child. 2009;94(11):823–826.
110. Skotko BG, Levine S P, Goldstein R. Having a son or daughter with Down syndrome: Perspectives from mothers and fathers. Am J Med Genet A. 2011;155A(10):2335–4237.
111. Illumina [homepage on the Internet]. Illumina files new patent infringement suit against ariosa diagnostics, Inc [press release]. [April 25, 2014]. Available from: http://investor.illumina.com/phoenix. zhtml?c=121127&p=irol-newsArticle&ID=1922600&highlight=. Accessed August 25, 2014.
112. Graff GD, Phillips D, Lei Z, Oh S, Nottenburg C, Pardey PG. Not quite a myriad of gene patents. Nature Biotechnology. 2013;31(5): 404–410.
113. Sayres LC, Allyse M, Goodspeed TA, Cho MK. In the public interest? Sci Transl Med. 2012;4(144):144fs23.
114. Cook-Deegan R, Chandrasekharan S, Angrist M. The dangers of diagnostic monopolies. Nature. 2009;458(7237):405–406.
115. Cho M. Patently unpatentable: Implications of the myriad court decision on genetic diagnostics. Trends Biotechnol. 2010;28(11):548–551.
116. Cook-Deegan R, Conley JM, Evans J P, Vorhaus D. The next controversy in genetic testing: Clinical data as trade secrets? Eur J Hum Genet. 2013;21(6):585–588.
117. Ray T. Amid ‘chaos,’ FDA’s gutierrez offers insights on agency’s regulatory stance on molecular tests. GenomeWeb. February 13, 2013. Available from: http://www.genomeweb.com/clinical-genomics/ amid-chaos-fdas-gutierrez-offers-insights-agencys-regulatory-stance-molecular-te. Accessed August 29, 2014.
118. Moreau C, Trussell J, Desfreres J, Bajos N. Medical vs Surgical abortion: the importance of women’s choice. Contraception. 2011; 84(3):224–229.
119. Wu Z, Viisainen K, Li X, Hemminki E. Maternal care in rural China: A case study from anhui province. BMC Health Serv Res. 2008;8:55.
120. Lu J, Shen JJ, Chen G, et al. Regional disparities in prenatal care services in rural China. Asia Pac J Public Health. 2011;23(5):682–689.
121. Tischler R, Hudgins L, Blumenfeld YJ, Greely HT, Ormond KE. Noninvasive prenatal diagnosis: Pregnant women’s interest and expected uptake. Prenat Diagn. 2011;31(13):1292–1299.
122. Sayres LC, Allyse M, Goodspeed TA, Cho MK. Demographic and experiential correlates of public attitudes towards cell-free fetal DNA screening. J Genet Couns. Epub April 9, 2014.
123. Verma IC, Lall M, Dua Puri R. Down syndrome in India – diagnosis, screening, and prenatal diagnosis. Clin Lab Med. 2012;32(2):231–248.
124. Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their frst child later in life. NCHS Data Brief. 2009;(21):1–8.
125. Al-Herz W, Al-Mousa H. Combined immunodefciency: The Middle East experience. J Allergy Clin Immunol.2013;131(3):658–660.
126. Abolghasemi H, Amid A, Zeinali S, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Oncol. 2007;29(4):233–238.
127. Diallo DA, Guindo A. Sickle cell disease in sub-Saharan Africa: Stakes and strategies for control of the disease. Curr Opin Hematol. 2014;21(3):210–214.
128. He S, Li D, Lai Y, et al. Prenatal diagnosis of β-thalassemia in Guangxi Zhuang autonomous region, China. Arch Gynecol Obstet. 2014;289(1):61–65.
129. Fox D. Prenatal screening policy in international perspective: Lessons from Israel, Cyprus, Taiwan, China, and Singapore. Yale Journal of Health Policy, Law, and Ethics. 2013;9(2):5.
130. Christianson A, Modell B. Medical genetics in developing countries. Annu Rev Genomics Hum Genet. 2004;5:219–265.
131. Abou-Zahr CL, Wardlaw TM. Antenatal care in developing countries: Promises, achievements and missed opportunities-an analysis of trends, levels and differentials, 1990–2001. WHO; 2003.
132. Pathak PK, Singh A, Subramanian S V. Economic inequalities in maternal health care: Prenatal care and skilled birth attendance in India, 1992–2006. PLoS One. 2010;5(10):e13593.
133. Bischoff FZ, Lewis DE, Simpson JL. Cell-free fetal DNA in maternal blood: Kinetics, source and structure. Hum Reprod Update. 2005;11(1):59–67.
134. Wong AE, Kuppermann M, Creasman JM, Sepulveda W, Vargas JE. Patient and provider attitudes toward screening for down syndrome in a Latin American country where abortion is illegal. Int J Gynaecol Obstet. 2011;115(3):235–239.
135. Ventura W, Nazario-Redondo C, Sekizawa A. Non-invasive prenatal diagnosis from the perspective of a low-resource country. Int J Gynaecol Obstet. 2013;122(3):270–273.
136. Sahota DS, Leung WC, Chan WP, To W W, Lau ET, Leung TY. Prospective assessment of the Hong Kong hospital authority universal down syndrome screening programme. Hong Kong Med J. 2013;19(2): 101–108.
137. Wang P, Michaels CA. Chinese families of children with severe disabilities: Family needs and available support. Research and Practice for Persons with Severe Disabilities. 2009;34(2):21–32.
138. Bittles AH, Glasson EJ. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol. 2004;46(4):282–286.
139. Holroyd EE. Chinese cultural infuences on parental caregiving obligations toward children with disabilities. Qual Health Res. 2003;13(1): 4–19.
140. Su B, Macer DR. Chinese people’s attitudes towards genetic diseases and children with handicaps. Rev Derecho Genoma Hum. 2003;(18): 191–210.
141. Chen SJ. China cracks down on DNA testing. Forbes. March 3, 2014. Available from http://www.forbes.com/sites/shuchingjeanchen/2014/ 03/03/china-cracks-down-on-dna-testing-2/. Accessed August 25, 2014.
142. GenomeWeb Staff Writer. BGI suspends clinical ngs-based trisomy testing in china. GenomeWeb. March 4, 2014. http://www.genomeweb.com/sequencing/bgi-suspends-clinical-ngs-based-trisomy-testing-china
143. Genomeweb [webpage on Internet]. China FDA Approves BGI’s NGS Products. July 02, 2104. Available from: http://www.genomeweb.com/ sequencing/china-fda-approves-bgis-ngs-products. Accessed August, 29 2014.
144. Ballantyne A, Newson A, Luna F, Ashcroft R. Prenatal diagnosis and abortion for congenital abnormalities: Is it ethical to provide one without the other? Am J Bioeth. 2009;9(8):48–56.
145. Finer L, Fine JB. Abortion law around the world: Progress and pushback. Am J Public Health. 2013;103(4):585–589.
146. Finlay JE, Canning D, Po JY. Reproductive health laws around the world. Program on the Global Demography of Aging. 2012. Available from: http://www.hsph.harvard.edu/pgda/wp-content/uploads/ sites/1288/2013/10/PGDA_WP_96.pdf. Accessed August 25, 2104.
147. Boland R, Katzive L. Developments in laws on induced abortion: 1998–2007. Int Fam Plan Perspect. 2008;34(3):110–120.
148. Abbasi M, Gooshki ES, Allahbedashti N. Abortion in Iranian legal system. Iran J Allergy Asthma Immunol. 2014;13(1):71–84.
149. Sedgh G, Singh S, Shah IH, Åhman E, Henshaw SK, Bankole A. Induced abortion: Incidence and trends worldwide from 1 995 to 2 008. Lancet. 2012;379(9816):625–632.
150. Bernabé-Ortiz A, White PJ, Carcamo C P, et al. Clandestine induced abortion: prevalence, incidence and risk factors among women in a Latin american country. CMAJ. 2009;180(3):298–304.
151. World Health Organization [homepage on the Internet]. Unsafe abortion: Global and regional estimates of incidence of unsafe abortion and associated mortality in 2008. Available from http://www.who.int/reproductivehealth/publications/unsafe_abortion/9789241501118/en/. Accessed June 15, 2014.
152. Fletcher R. Peripheral governance: Administering transnational health-care fows. International Journal of Law in Context. 2013;9(2): 160–191.
153. Palmer B. “Lonely, tragic, but legally necessary pilgrimages”: transnational abortion travel in the 1970s. Can Hist Rev. 2011;92(4): 637–664.
154. Hvistendahl M. Unnatural Selection: Choosing Boys Over Girls, and The Consequences of A World Full of Men. Reprinted. New York: Public Affairs; 2011.
155. Kay M. Five Tamil Nadu doctors banned from practice for violating prenatal sex selection law. BMJ. 2013;346:f3788.
156. Ministry of Health and Family Welfare, Government of India [homepage on the Internet]. Annual report on implementation of the pre-conception and pre-natal diagnostic techniques (prohibition of sex selection) act 2005. Available from: http://india.unfpa.org/drive/ IMPLEMENTATIONOFTHEPCPNDTACTININDIAPerspective-sandChallenges.pdf. Accessed June 15, 2014.
157. Nandi A, Deolalikar AB. Does a legal ban on sex-selective abortions improve child sex ratios? Evidence from a policy change in India. Journal of Development Economics. 2013;103:216–228.
158. Madan K, Breuning MH. Impact of prenatal technologies on the sex ratio in India: An overview. Genet Med. 2014;16(6):425–432.
159. Jain A. Sex selection and abortion in India. BMJ. 2013;346:f1957.
160. Nie JB. Limits of state intervention in sex-selective abortion: The case of China. Cult Health Sex. 2010;12(2):205–219.
161. French BH. As girls ‘vanish,’ Chinese city battles tide of abortions. N Y Times Web. 2005:A3.
162. Gupta MD, Zhenghua J, Bohua L, Zhenming X, Chung W, Hwa-Ok B. Why is son preference so persistent in east and south Asia? A crosscountry study of China, India and the republic of Korea. The Journal of Development Studies. 2003;40(2):153–187.
163. Hesketh T, Lu L, Xing Z W. The consequences of son preference and sex-selective abortion in china and other Asian countries. CMAJ. 2011;183(12):1374–1377.
164. Plafker T. Sex selection in China sees 1 17 boys born for every 1 00 girls. BMJ. 2002;324(7348):1233.
165. Nie JB. Non-medical sex-selective abortion in china: Ethical and public policy issues in the context of 40 million missing females. Br Med Bull. 2011;98(1):7–20.
166. Lai-wan CC, Blyth E, Hoi-yan CC. Attitudes to and practices regarding sex selection in China. Prenat Diagn. 2006;26(7):610–613.
167. Pinghui Z. Zhejiang man arrested for arranging sex tests in Hong Kong for pregnant mainland women. South China Morning Post. April 18, 2014.